Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

This is a prospective, single-arm trial. The main purpose of the study is to evaluate the efficacy and safety of Nimotuzumab combined with nab-paclitaxel+ gemcitabine (AG regimen) for postoperative adjuvant treatment of pancreatic cancer with EGFR-positive.

Trial Details

NCT ID
NCT06722911
Phase
PHASE2
Sponsor
Zhejiang Provincial People's Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Nimotuzumab
  • AG
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • 1\. Able and willing to provide a written informed consent.
  • 2\. Age 18-75 years old, gender unlimited;
  • 3\. Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN …
  • 4\. Postoperative pathology suggested R0/R1 resection;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →